MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

32.25 -0.37 (-1.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 254,480
Open 32.43
Bid (Size) 30.00 (200)
Ask (Size) 33.30 (400)
Prev. Close 32.62
Today's Range 31.51 - 32.82
52wk Range 19.56 - 36.60
Shares Outstanding 33,816,459
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over? ↗
This late-stage biotech innovator in rare disease therapies reported significant insider selling amid strong one-year share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
From Pharvaris N.V.
Via GlobeNewswire

Performance

YTD
+21.8%
+21.8%
1 Month
-2.9%
-2.9%
3 Month
+7.4%
+7.4%
6 Month
+17.6%
+17.6%
1 Year
+51.9%
+51.9%

More News

Read More
News headline image
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones ↗
Via Chartmill
News headline image
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Annual General Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
From Pharvaris N.V.
Via GlobeNewswire
News headline image
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors. ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
Via The Motley Fool
News headline image
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
Via The Motley Fool
News headline image
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Outlines 2026 Strategic Priorities
From Pharvaris N.V.
Via GlobeNewswire
News headline image
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗
Via The Motley Fool

Frequently Asked Questions

Is Pharvaris N.V. - Ordinary Shares publicly traded?
Yes, Pharvaris N.V. - Ordinary Shares is publicly traded.
What exchange does Pharvaris N.V. - Ordinary Shares trade on?
Pharvaris N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Pharvaris N.V. - Ordinary Shares?
The ticker symbol for Pharvaris N.V. - Ordinary Shares is PHVS on the Nasdaq Stock Market
What is the current price of Pharvaris N.V. - Ordinary Shares?
The current price of Pharvaris N.V. - Ordinary Shares is 32.25
When was Pharvaris N.V. - Ordinary Shares last traded?
The last trade of Pharvaris N.V. - Ordinary Shares was at 08/03/26 04:00 PM ET
What is the market capitalization of Pharvaris N.V. - Ordinary Shares?
The market capitalization of Pharvaris N.V. - Ordinary Shares is 1.09B
How many shares of Pharvaris N.V. - Ordinary Shares are outstanding?
Pharvaris N.V. - Ordinary Shares has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story